Key facts
- Jupiter Endovascular’s last known valuation is $96.0M (Oct 2025).
- It has raised $60.8M; the latest was Early Stage VC ($40.0M) in Oct 2025.
- Notable investors include InterVest, LB Investment, Mighty Capital, Sonder Capital Management, SCP Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Jupiter Endovascular
- ·The full record, as it builds
Funding rounds
No funding rounds for Jupiter Endovascular are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Jupiter Endovascular
Developer of catheter technology designed to bring control and precision to catheter interventions. The company's technology mimics the precision and control of direct surgical access in catheter therapies, enabling healthcare professionals to overcome the limitations of catheters.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2024
- Employees
- 42
- Website
- jupiterendo.com/
- Ownership
- Privately Held (backing)
Jupiter Endovascular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jupiter Endovascular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jupiter Endovascular in its N-PORT filings yet. We sweep new filings monthly.